Takeda’s Deleveraging Begins with Ethicon and Novartis Deals
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 5 (Table of Contents)
Published: 14 May-2019
DOI: 10.3833/pdr.v2019.i5.2424 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Takeda has agreed to divest two of its non-core assets in a bid to streamline its portfolio to focus on its four core business areas...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS